| dbo:abstract |
ريدنيلازول (المعروف سابقًا باسم SMT19969) هو مضاد حيوي ذو جزيء صغير تجريبي يتم تقييمه للإعطاء عن طريق الفم لعلاج عدوى المطثيات العسيرة (CDI). في المختبر ، هو مبيد للجراثيم ضد المطثية العسيرة ويثبط إنتاج السموم البكتيرية ؛ يعتقد أن آلية العمل تتضمن تثبيط انقسام الخلايا. (ar) Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic being evaluated for oral administration to treat Clostridioides difficile infection (CDI). In vitro, it is bactericidal against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell division. It has properties which are desirable for the treatment of CDI, namely that it is a narrow-spectrum antibiotic which exhibits activity against C. difficile while having little impact on other normal intestinal flora and that it is only minimally absorbed systemically after oral administration. At the time ridinilazole was developed, there were only three antibiotics in use for treating CDI: vancomycin, fidaxomicin, and metronidazole. The recurrence rate of CDI is high, which has spurred research into other treatment options with the aim to reduce the rate of recurrence. As of 2019, two phase II trials have been completed and two phase III trials comparing ridinilazole to vancomycin for CDI are expected to be completed in September 2021. Ridinilazole was designated as a Qualified Infectious Disease Product (QIDP) and was granted Fast Track status by the U.S. FDA. Fast Track status is reserved for drugs designed to treat diseases where there is currently a gap in the treatment, or a complete lack thereof. The QIDP designation adds five more years of exclusivity for ridinazole upon approval. (en) |
| dbo:casNumber |
308362-25-6 |
| dbo:fdaUniiCode |
06DX01190R |
| dbo:kegg |
D11958 |
| dbo:pubchem |
16659285 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Ridinilazole.svg?width=300 |
| dbo:wikiPageID |
49575625 (xsd:integer) |
| dbo:wikiPageLength |
6032 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120555914 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Bacterial_toxin dbr:Antibiotic dbr:Vancomycin dbr:In_vitro dbr:Qualified_Infectious_Disease_Product dbc:Antibiotics dbr:Small_molecule dbr:Phase_II_trials dbr:Clostridioides_difficile_infection dbr:Bactericidal dbc:4-Pyridyl_compounds dbc:Benzimidazoles dbr:Fidaxomicin dbr:Food_and_Drug_Administration dbr:Fast_track_(FDA) dbr:Metronidazole dbr:Mechanism_of_action dbr:Narrow-spectrum_antibiotic dbr:Intestinal_flora |
| dbp:atcPrefix |
None (en) |
| dbp:c |
24 (xsd:integer) |
| dbp:casNumber |
308362 (xsd:integer) |
| dbp:chemspiderid |
17592423 (xsd:integer) |
| dbp:h |
16 (xsd:integer) |
| dbp:iupacName |
22 (xsd:integer) |
| dbp:kegg |
D11958 (en) |
| dbp:n |
6 (xsd:integer) |
| dbp:pubchem |
16659285 (xsd:integer) |
| dbp:smiles |
c6ccccn6 (en) |
| dbp:synonyms |
SMT19969 (en) |
| dbp:unii |
6 (xsd:integer) |
| dbp:width |
275 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:As_of dbt:Infobox_drug dbt:Reflist dbt:Fdacite |
| dcterms:subject |
dbc:Antibiotics dbc:4-Pyridyl_compounds dbc:Benzimidazoles |
| gold:hypernym |
dbr:Molecule |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:ChemicalCompound dbo:Drug |
| rdfs:comment |
ريدنيلازول (المعروف سابقًا باسم SMT19969) هو مضاد حيوي ذو جزيء صغير تجريبي يتم تقييمه للإعطاء عن طريق الفم لعلاج عدوى المطثيات العسيرة (CDI). في المختبر ، هو مبيد للجراثيم ضد المطثية العسيرة ويثبط إنتاج السموم البكتيرية ؛ يعتقد أن آلية العمل تتضمن تثبيط انقسام الخلايا. (ar) Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic being evaluated for oral administration to treat Clostridioides difficile infection (CDI). In vitro, it is bactericidal against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell division. It has properties which are desirable for the treatment of CDI, namely that it is a narrow-spectrum antibiotic which exhibits activity against C. difficile while having little impact on other normal intestinal flora and that it is only minimally absorbed systemically after oral administration. At the time ridinilazole was developed, there were only three antibiotics in use for treating CDI: vancomycin, fidaxomicin, and metronidazole. The recurre (en) |
| rdfs:label |
ريدنيلازول (ar) Ridinilazole (en) |
| owl:sameAs |
yago-res:Ridinilazole wikidata:Ridinilazole dbpedia-ar:Ridinilazole https://global.dbpedia.org/id/2MvQZ |
| prov:wasDerivedFrom |
wikipedia-en:Ridinilazole?oldid=1120555914&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ridinilazole.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Ridinilazole |
| is dbo:wikiPageRedirects of |
dbr:C24H16N6 |
| is dbo:wikiPageWikiLink of |
dbr:Robert_Duggan_(venture_capitalist) dbr:Clostridioides_difficile_infection dbr:C24H16N6 |
| is foaf:primaryTopic of |
wikipedia-en:Ridinilazole |
